Scott IU, et al. - The visual acuity letter score and central subfield thickness outcomes of participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial were compared by the experts who then received either monthly injections or treat-and-extend (TAE) regimens of aflibercept or bevacizumab following a good response at month 6. In months 6 to 12, one to 2 fewer injections of aflibercept or bevacizumab were given to the TAE groups than the monthly groups for macular edema related to the central retinal or hemiretinal vein occlusion. Before concluding that the regimens were related to similar vision outcomes, caution was warranted, because of wide confidence intervals on the differences between the groups.